Therefore, manipulation with CCL23 may help reprogram the HCC TME by targeting myeloid checkpoints to harness the power of antitumor immunity with immune checkpoint inhibitors or other forms of immunotherapy approaches. The gene discussed is CCL23; the disease is hepatocellular carcinoma.